Remus Pharmaceuticals Ltd. · NSE:REMUS
Remus Pharmaceuticals — H2 FY2024-25 Earnings Presentation
27 slides from Remus Pharmaceuticals's earnings presentation, 2025
Slide 1: Earnings Presentation H2 & FY 2024-25
Earnings Presentation H2 & FY 2024-25 We believe in creating a positive difference in people’s lives. www.remuspharma.com
Slide 2: Contents
H2 & FY 2024-25 1 Performance Highlights 2 Company Overview Contents 3 Business Overview 4 Financial Overview
Slide 3: Performance Highlights
H2 & FY 2024-25 Performance Highlights
Slide 4: Consolidated Financial Highlights (H2)
Financial Highlights Operational Revenue (INR Cr.) EBITDA (INR Cr.) PAT (INR Cr.) 348 27 Consolidated 21 21 19 185 H2-FY24 H2-FY25 H2-FY24 H2-FY25 H2-FY24 H2-FY25 Operational Revenue (INR Cr.) EBITDA (INR Cr.) PAT (INR Cr.) 41 15 11 Standalone 36 13 9 H2-FY24 H2-FY25 H2-FY24 H2-FY25 H2-FY24 H2-FY25
Slide 5: Consolidated Financial Highlights (FY)
Financial Highlights Operational Revenue (INR Cr.) EBITDA (INR Cr.) PAT (INR Cr.) 620 38 50 Consolidated 24 32 213 FY24 FY25 FY24 FY25 FY24 FY25 Operational Revenue (INR Cr.) EBITDA (INR Cr.) PAT (INR Cr.) 79 29 20 Standalone 64 23 17 FY24 FY25 FY24 FY25 FY24 FY25
Slide 6: H2 & FY 2024-25 Operational Highlights
H2 & FY 2024-25 Operational Highlights Built a strong global brand portfolio with 170 trademarks filed and 35+ approvals secured. Successfully commercialized 10+ recently off-patent niche pharmaceutical products. Commenced product registration in Bosnia and Herzegovina, Kosovo, Mexico, Tanzani
Slide 7: Event Highlights
Event Highlights Awareness Event for gynecologists, Brand Awareness Conference Farmacorp Conferance and general practitioners, and with 55+ doctors and pharmacy Training Event - December 2024 hematologists in Oruro - March 2025 representatives October - 2024 Promotional event with Farma Elías St. Ag
Slide 8: Half Yearly Standalone Income Statement
HALF YEARLY STANDALONEFinancial INCOME Highlights STATEMENT PARTICULARS (INR Cr.) H2-FY25 H2-FY24 Y-O-Y H1-FY25 H-O-H Operational Revenue 41 36 13.9% 38 7.9% Other Income 1 1 NA 2 (50.0)% Operating Expenses 27 24 12.5% 27 NA 15 13 15.4% 13 15.4% EBITDA Operational EBITDA Margin (%) 36.59% 36.11% 48
Slide 9: YTD Standalone Income Statement
YTD STANDALONE INCOMEFinancial STATEMENTHighlights PARTICULARS (INR Cr.) FY25 FY24 Y-O-Y Operational Revenue 79 64 23.4% Other Income 3 3 NA Operating Expenses 53 44 20.5% EBITDA 29 23 26.1% EBITDA Margin (%) 36.71% 35.94% 77 Bps Depreciation and Amortisation 2 1 NA Finance costs - - NA PBT 27 22 22
Slide 10: Half Yearly Consolidated Income Statement
Financial HALF YEARLY CONSOLIDATED INCOMEHighlights STATEMENT PARTICULARS (INR Cr.) H2-FY25 H2-FY24 Y-O-Y H1-FY25 H-O-H Operational Revenue 348 185 88.1% 273 27.5% Other Income 3 1 NA 2 50.0% Operating Expenses 324 165 96.4% 251 29.1% EBITDA 27 21 28.6% 24 12.5% EBITDA Margin (%) 7.76% 11.35% (359)
Slide 11: YTD Consolidated Income Statement
Financial YTD CONSOLIDATED INCOME Highlights STATEMENT PARTICULARS (INR Cr.) FY25 FY24 Y-O-Y Operational Revenue 620 213 NA Other Income 5 3 66.7% Operating Expenses 575 184 NA Operational EBITDA 50 32 56.3% Operational EBITDA Margin (%) 8.06% 15.02% (696) Bps Depreciation and Amortisation 2 1 NA Fi
Slide 12: Historical Consolidated Balance Sheet
Financial HISTORICAL CONSOLIDATED BALANCEHighlights SHEET ASSETS (INR Cr.) FY24 FY25 EQUITY & LIABILITIES (INR Cr.) FY24 FY25 Non-current assets Equity Share Capital 1 6 a)Property, Plant & Equipment and Reserve and Surplus 156 250 Intangible Assets Total Equity 157 256 i) Property, Plant & Equipmen
Slide 13: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS Net Debt to Equity (X) Working Capital Days 0.05 122 59 FY24 FY25 -0.01 FY24 FY25 Book Value Per share ROCE (%) & ROE (%) 434 15.99% 267 15.69% 15.41% 15.01% FY24 FY25 FY24 FY25 ROE ROCE Note: ROE & ROCE, Calculated on increased Capital base due to IND AS impact
Slide 14: Company Overview
Company Overview
Slide 15: Introduction to Remus
Introduction to Remus Comprehensive Pharmaceutical Solution • Remus specializes in the Complex Specialty and Niche Products Branding, Marketing and Distribution of approved finished formulations in various countries Expanding Portfolio • A growing portfolio of 620+ registered products, 640+ MOH subm
Slide 16: Introduction to Subsidiaries
Introduction to Subsidiaries • Strategic Positioning: Relius, as a brand, enhances last-mile • Espee is a US based WDD service provider that provide distribution, ensuring direct reach to consumers, with a supports to innovators, multinational generic manufacturers, differentiated product portfolio
Slide 17: Milestones
Milestones Initiated the export of finished • Acquired Espee USA • LATAM Expansion: Continue incorporating formulations and began subsidiaries in additional LATAM countries marketing efforts to introduce Initiated a focused presence in to deepen regional influence Remus as a competitive player selec
Slide 18: Board of Directors
Board of Directors Mr. Arpit Shah Mr. Swapnil Shah Ms. Roma Shah Ms. Anar Shah Managing Director Chairman & Whole-time Director Non-Executive Non-Independent Director* Non-Executive Non-Independent Director* Mr. Vishrut Pathak Ms. Sanjana Shah Mr. Balwant Purohit Non-Executive Independent Director N
Slide 19: Our Products
Our Products Injections Tablets Capsules (liquid & lyophilized, Ophthalmic Liquid Orals Sachets pre-filled syringes) Soft Gel Ointments, Powder for Inhalers Biosimilars Oncology Capsules Creams & Gels Injections & Sprays 19
Slide 20: Our Products
: Remus RELITRIL-Y.200 RELIBEGRON XR 25 ‘Mirabearon X°} RELIBEGRON XR 50 Bempedo! ror se ean 885070 ee 4 Eltropag 25 lets 180 mg oe gprolus i Eltrombopag Tablets 25 mg | Rempedoic | (fenpedoe seid eztimine ee 3 Tablets 180 mg + 10 mg sites fermuse | Rempedoic Plus [Pres EMPAREL M. 5/1000 tmparel M 1
Slide 21: Product Portfolio
Product Portfolio SKUs Dosage Form SKUs* (Mar-25) Tablets 973 Tablets Injectables 534 Injectables 48, 2% 26,125, 78, 4%1% 6% Hard Gel Capsules & Softgel Capsules 221 Hard Gel Capsules & Softgel 221, 11% 973, 49% Capsules Creams , Gels , Ointments & Topical Solutions 78 Creams , Gels , Ointments & To
Slide 22: Global Reach: Total 2000+
Global Reach 37 36 10 Under Filed Process 19 643 Registered Registered Africa Commonwealth of Registered Independent States 85 68 39 12 464 Under LATAM Process 1596 Filed Under Process Total 2000+ 489 111 Filed South East 7 Filed Asia 5 225 Registered Registered Middle East 23 107 12 6 Under Under p
Slide 23: Regulatory QC/QA
Regulatory QC/QA Expert Regulatory Affairs Team A highly skilled team of 30+ professionals, each specializing in key regions and complex products, including Oncology, Biosimilars, and Monoclonal Dynamic & Adaptive Team Antibodies (MAB). Young professionals driving innovation and complex molecule dev
Slide 24: Differentiating Factors
Swift Market Entry: Developing Brand Excellence: Registering recently off-patent products for and trademarking our First mover advantage own brands, building a regional presence Strategic Market Expansion: Global Tie-ups: Strong Venturing into untapped markets, which not only adds Differentiating st
Slide 25: Capital Market Data
Capital Market Data 1 YEAR SHARE PRICE MOVEMENT (UP TO 31st March 2025) 70% 60% 50% 40% 30% 20% 10% 0% -10% -20% -30% Apr-24 May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 REMUS Sensex PRICE DATA (As on 31st March 2025) SHAREHOLDING PATTERN (As on 31st March 2025) Face
Slide 26: Disclaimer
Disclaimer Remus Pharmaceuticals Ltd. Disclaimer: The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This Presentation has been prepared by
Slide 27: Thank You
Registered Office 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli -Bopal Road, Ahmedabad, Gujarat, India, 380054 CIN ISIN L24232GJ2015PLC084536 INE0O5T01011 : REMUS Thank You
Remus Pharmaceuticals — H2 FY2024-25 Earnings Presentation on 6ix